|Grant Number:||7R01CA114524-03 Interpret this number|
|Primary Investigator:||Penson, David|
|Project Title:||Race, Comorbidity & Long Term Prostate Cancer Outcomes|
DESCRIPTION (provided by applicant): The long-term effects (10 years or more) of prostate cancer and treatment on clinical and patient-reported outcomes are not well understood. Furthermore, as patients live longer after their diagnosis, they are developing co-morbid conditions, experiencing cancer recurrences or progression and receiving secondary cancer therapies, all of which can affect their health and quality of life. A better understanding of these clinical events and their effects is essential to designing interventions to improve quality of life and for informing newly-diagnosed patients. We propose to use an existing and unique resource to improve our understanding of prostate cancer survivorship: the Prostate Cancer Outcomes Study (PCOS). The PCOS is a population-based cohort of men with prostate cancer followed longitudinally since their diagnosis in 1994-5. The dataset includes clinical and sociodemographic data, information on treatment and health-related quality of life (HRQOL) outcomes. The proposed study has the following three aims: 1) To characterize long-term (10-15 year) clinical outcomes, including biochemical recurrence (prostate-specific antigen), clinical disease progression, use of secondary cancer therapies and the onset or worsening of co-morbid illnesses and/or skeletal related events in a population-based cohort of prostate cancer survivors. 2) To assess the associations between these clinical outcomes and long-term disease-specific and general HRQOL. 3) To assess the independent associations of race/ethnicity and socioeconomic status (SES) with long- term clinical and HRQOL outcomes. To achieve these aims, we will collect 14-year data on disease recurrence/progression, receipt of secondary therapy, co-morbidity (including skeletal related and cardiovascular events), medication use, functional status and HRQOL in the surviving members of the PCOS cohort. The current PCOS cohort includes 2,348 men with prostate cancer from 6 SEER registries who have been followed since diagnosis with patient- reported data collected at 6,12, 24 and 60 months. Descriptive statistics will be used to achieve the first aim. For the second and third aims, appropriate multivariable statistical methodology will be used. When completed, this study will be the longest population-based prospective follow-up of prostate cancer survivors yet reported in the literature and will provide important information for prostate cancer survivors, clinicians, researchers and healthcare policy makers. Specifically, it will help newly-diagnosed patients make more informed decisions regarding treatment and will help researchers design novel interventions to improve the quality of life of prostate cancer survivors.
The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research.
Authors: Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF
Source: Eur Urol, 2014 Aug 28;null, p. null.
EPub date: 2014 Aug 28.
Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.
Authors: Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Penson DF
Source: Prostate Cancer Prostatic Dis, 2014 Aug 19;null, p. null.
EPub date: 2014 Aug 19.
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
Authors: Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Litwin MS, Penson DF
Source: Ann Intern Med, 2013 May 21;158(10), p. 709-17.
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer.
Authors: Hoffman RM, Koyama T, Fan KH, Albertsen PC, Barry MJ, Goodman M, Hamilton AS, Potosky AL, Stanford JL, Stroup AM, Penson DF
Source: J Natl Cancer Inst, 2013 May 15;105(10), p. 711-8.
EPub date: 2013 Apr 24.
Long-term functional outcomes after treatment for localized prostate cancer.
Authors: Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF
Source: N Engl J Med, 2013 Jan 31;368(5), p. 436-45.
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Authors: Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, Penson DF
Source: BJU Int, 2013 Feb;111(2), p. 213-20.
EPub date: 2012 Aug 29.
The Patient Protection and Affordable Care Act: the impact on urologic cancer care.
Authors: Keegan KA, Penson DF
Source: Urol Oncol, 2013 Oct;31(7), p. 980-4.
EPub date: 2012 Jul 21.
Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study.
Authors: Thong MS, van de Poll-Franse L, Hoffman RM, Albertsen PC, Hamilton AS, Stanford JL, Penson DF
Source: BJU Int, 2011 Apr;107(8), p. 1223-31.
EPub date: 2010 Nov 11.
Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap.
Authors: Barocas DA, Penson DF
Source: BJU Int, 2010 Aug;106(3), p. 322-8.
EPub date: 2010 Jun 14.
Health related quality of life for men treated for localized prostate cancer with long-term followup.
Authors: Huang GJ, Sadetsky N, Penson DF
Source: J Urol, 2010 Jun;183(6), p. 2206-12.
Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.
Authors: Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA
Source: J Clin Oncol, 2010 Feb 20;28(6), p. 1069-74.
EPub date: 2010 Jan 25.
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
Authors: FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG
Source: BMC Cancer, 2008 Aug 11;8, p. 230.
EPub date: 2008 Aug 11.